

NEWS RELEASE

**Teijin and Jolly Good to Jointly Develop
VR-based Depression-treatment System**

Tokyo, Japan, April 23, 2021 --- [Teijin Pharma Limited](#), the core company of the [Teijin Group](#)'s healthcare business, announced today that it has signed a contract with Jolly Good Inc. to jointly develop a safe and effective cognitive-behavioral-therapy virtual-reality (CBT-VR) system for anti-depression therapy, for which they intend to seek regulatory approval.



Conceptual image of envisioned CBT-VR system

Jolly Good won the Home Healthcare Award on healthcare business co-creation program, which Teijin Pharma conducted in December 2020. Since then the two companies have identified an opportunity to develop a CBT-VR system based on their mutual strengths and expertise. The collaboration will combine Teijin Pharma's knowledge and technology and Jolly Good's VR technology in an effort to help mental-illness professionals improve the quality of life for patients suffering from depression.

Thinking, reacting and other cognitive behavior affect mood and behavior. CBT, an alternative therapy for depression, is a psychotherapy in which medical personnel help patients learn how to correct maladaptive thinking and solve problems positively and practically * Teijin Pharma and Jolly Good now plan to develop a CBT-VR therapy based on a combination of VR and clinical guidance. VR will be used to help patients with emotional arousal, aiming at both improved therapeutic effects and reduced therapeutic burdens in CBT for medical personnel as well as patients.

* "Research on the Implementation Method and Effectiveness of Psychotherapy," Health Science and Labor Research Grants on Mental Health Science Research Project

Teijin Pharma contributes to society by developing advanced services that help to alleviate unresolved needs in the field of depression treatment. The company is a member of the Teijin Group, which creates innovative products and services that support

healthy and comfortable lives in people of all ages. Teijin Pharma, which plays a central role in the group's healthcare business, has been selling the *Neurostar*[®] transcranial magnetic stimulation (TMS) device for depression-related mental illness treatment in Japan since 2019.

Jolly Good is a medical technology company that develops VR-based medical solutions and artificial intelligence (AI) services for analysis of patient behavior in VR spaces. Its VR and AI technologies are accelerating understanding of and related support and treatments for mental illness. In collaboration with research institutes and other enterprises, Jolly Good also develops services to further mental illness care and the abilities of patients to cope with the disease.

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fields of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Originally established as Japan's first rayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing three core business domains: high-performance materials including aramid, carbon fibers and composites, and also resin and plastic processing, films, polyester fibers and products converting; healthcare including pharmaceuticals and home healthcare equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare; and IT including B2B solutions for medical, corporate and public systems as well as packaged software and B2C online services for digital entertainment. Deeply committed to its stakeholders, as expressed in the brand statement "Human Chemistry, Human Solutions", Teijin aims to be a company that supports the society of the future. The group comprises more than 170 companies and employs some 20,000 people across 20 countries worldwide. Teijin posted consolidated sales of JPY 853.7 billion (USD 8.0 billion) and total assets of JPY 1,004.2 billion (USD 9.4 billion) in the fiscal year that ended on March 31, 2020.

Press Contact

Corporate Communications

Teijin Limited

pr@teijin.co.jp